| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0269216310385601 |
| P698 | PubMed publication ID | 21708858 |
| P2093 | author name string | Giovambattista Zeppetella | |
| P2860 | cites work | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Impact and management of breakthrough pain in cancer | Q34975545 | ||
| Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain | Q36609652 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. | Q39321110 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study | Q39441138 | ||
| Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain | Q39444283 | ||
| Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients | Q39449130 | ||
| An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain | Q40797392 | ||
| Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 | ||
| Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate | Q48618437 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | opioid | Q427523 |
| pain management | Q621261 | ||
| systematic review | Q1504425 | ||
| cancer pain | Q3712728 | ||
| P304 | page(s) | 516-524 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Palliative Medicine | Q7127852 |
| P1476 | title | Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project | |
| P478 | volume | 25 |
| Q90259962 | Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer |
| Q38211002 | Breakthrough pain in elderly patients with cancer: treatment options |
| Q37407492 | Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain |
| Q38086150 | Cancer pain management: what's new? |
| Q38106698 | Fentanyl for the treatment of tumor-related breakthrough pain. |
| Q39652268 | Fentanyl pectin nasal spray for breakthrough cancer pain |
| Q39226460 | Fentanyl sublingual spray for breakthrough pain in cancer patients |
| Q38084114 | Grading clinical guidelines for the use of transmucosal immediate-release fentanyl products in breakthrough pain |
| Q98892344 | Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part II) |
| Q58779833 | Intravenous morphine titration vs. oral hydrocodone/acetaminophen for adults with lower extremity displaced fracture in an emergency department setting: A randomized controlled trial |
| Q38210362 | Management of pain in advanced disease |
| Q35911309 | NICE Opioids in Palliative Care (Clinical Guideline 140) - A Guideline Summary |
| Q34131342 | Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain |
| Q39179543 | Ultrasound-Guided Radiofrequency Treatment of Intercostal Nerves for the Prevention of Incidental Pain Arising Due to Rib Metastasis |
| Q34251507 | Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. |
| Q28069133 | What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion |
| Q53688489 | [Breakthrough pain and short-acting opioids]. |
| Q85937335 | [Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency] |
| Q87176323 | [Questions from a pain physician reader: Evidence, empiricism, eminence - all the same?] |
Search more.